In vitro assessment of Gentian violet anti-Candida activity

Gynecologic and Obstetric Investigation

Volumn 74, Issue 2, 2012, Pages 120-124

  Gomes De Elvas, A R ^a   Palmeira De Oliveira, A ^a   Gaspar, C ^a   Gouveia, P ^a,b   Palmeira De Oliveira, R ^a   Pina Vaz, C ^c   Rodrigues, A G ^c   Martinez De Oliveira, J ^a,b  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b Hospital Center Cova da Beira   (Portugal)

^c University of Porto   (Portugal)

Author keywords

Antibiotherapy; Candida; Gentian violet; Vulvovaginal candidosis

Indexed keywords

CRYSTAL VIOLET; PROPIDIUM IODIDE;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS; CELL MEMBRANE; FLOW CYTOMETRY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VAGINA CANDIDIASIS;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS; CANDIDIASIS, VULVOVAGINAL; FEMALE; FLUCONAZOLE; GENTIAN VIOLET; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84866743214     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000338899     Document Type: Article

References (33)

1. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203-211.
2. Mardh PA, Rodrigues AG, Genc M, Noviko-va N, Martinez-de-Oliveira J, Guaschino S: Facts and myths on recurrent vulvovaginal candidosis-a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002;13: 522-539.
3. Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55:1-94.
4. Sobel JD: Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges. Drug Resist Updat 1999;2:148-152.
5. Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G: Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gyne-col 1997;176:138-141.
6. Fidel PL, Vazquez JA, Sobel JD: Candida gla-brata: an important fungal pathogen for the 21st century. Clin Microbiol Newslett 2001; 23.
7. Rogers TR: Antifungal drug resistance: does it matter? Int J Infect Dis 2002; 6(suppl 1): S 47-S53.
8. Rogers TR: Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 2006; 27(suppl 1):7-11.
9. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, Stalpaert M, Vereeck-en A, Van Eldere J: Individualized decreas-ing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (Re-CiDiF trial). Am J Obstet Gynecol 2008;199: 613 e1-9.
10. Shahid Z, Sobel JD: Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candi-diasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009;64: 354-356.
11. Das Neves J, Pinto E, Teixeira B, Dias G, Ro-cha P, Cunha T, Santos B, Amaral M H, Bahia MF: Local treatment of vulvovaginal candi-dosis: general and practical considerations. Drugs 2008;68:1787-802.
12. Palmeira-de-Oliveira A, Salgueiro L, Pal-meira-de-Oliveira R, Martinez-de-Oliveira J, Pina-Vaz C, Queiroz JA, Rodrigues AG: Anti-Candida activity of essential oils. Mini Rev Med Chem 2009;9: 1292-1305.
13. Lima O, Oliveira RAG, Lima EO, Farias NMP, Souza EL: Atividade antifúngica de óleos essenciais sobre espécies de Candida. Rev Bras Fa rmacogn 2006;16: 197-201.
14. Palmeira-de-Oliveira A, Ribeiro MP, Pal-meira-de-Oliveira R, Gaspar C, Costa-de-Oliveira S, Correia IJ, Pina-Vaz C, Martinez Oliveira J, Queiroz JA, Rodrigues AG: Anti-Candida activity of a chitosan hydrogel: mechanism of action and cytotoxicity profile. Gynecol Obstet Invest 2010;70:322-327.
15. Pinto E, Pina-Vaz C, Salgueiro L, Goncalves MJ, Costa-de-Oliveira S, Cavaleiro C, Pal-meira A, Rodrigues A, Martinez-de-Oliveira J: Antifungal activity of the essential oil of Thymus pulegioides on Candida, Aspergillus and dermatophyte species. J Med Microbiol 2006;55:1367-1373.
16. Das Neves J, Pinto E, Amaral M, Bahia M: Antifungal activity of a gel containing Thymus vulgaris essential oil against Candida species commonly involved in vulvovaginal candidosis. Pharm Biol 2009;47:151-153.
17. White DJ, Johnson EM, Warnock DW: Management of persistent vulvovaginal candido-sis due to azole-resistant Candida glabrata. Genitourin Med 1993;69:112-114.
18. Urdaneta E, Benaim Pinto V, Gavaller B: Candidiasis. Mycopathologia 1961;15:317-342.
19. Traboulsi RS, Mukherjee PK, Ghannoum MA: In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients. Int J Antimicrob Agents 2008;31:272-276.
20. Ying S, Qing S, Chunyang L: The effect of gentian violet on virulent properties of Candida albicans. Mycopathologia 2010;169: 279-285.
21. CETEMED-ANF: For mulário Galénico Por-tuguês. Lisboa, Centro Tecnológico do Me-dicamento and Associação Nacional de Farmácias, 2005, vol 1, p 5.
22. CLSI: Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard, ed 3; in CLSI Document M27-A3. Wayne/PA, Clinical and Laboratory Standard Institute, 2008.
23. Canton E, Peman J, Viudes A, Quindos G, Gobernado M, Espinel-Ingroff A: Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Mi-crobiol Infect Dis 2003;45:203-206.
24. Pina-Vaz C, Rodrigues AG: Evaluation of an-tifungal susceptibility using flow cytometry. Met hods Mol Biol 2010;638: 281-289.
25. Rosenkranz HS, Carr HS: Possible hazard in use of gentian violet. Br Med J 1971;iii:702-703.
26. Wolfe AD: Influence of cationic triphenyl-methane dyes upon DNA polymerization and product hydrolysis by Escherichia coli polymerase I. Biochemistry 1977;16: 30-33.
27. Harrelson WG Jr, Mason RP: Microsomal reduction of gentian violet. Evidence for cyto-chrome P450-catalyzed free radical formation. Mol Pharmacol 1982;22: 239-242.
28. Littlefield NA, Blackwell BN, Hewitt CC, Gaylor DW: Chronic toxicity and carcinoge-nicity studies of gentian violet in mice. Fun-dam Appl Toxicol 1985;5:902-912.
29. Tolba MK, Saleh AM: Studies on the mechanism of fungicidal action of crystal violet on mycelial felts of Fusarium culmorum. Arch Mikrobiol 1963;47:201-206.
30. Shrand H: Thrush in the newborn. Br Med J 1961;ii:1530-1533.
31. Donders GG, Bellen G, Mendling W: Management of recurrent vulvo-vaginal candi-dosis as a chronic illness. Gynecol Obstet Invest 2010;70: 306-321.
32. Wright SC, Maree JE, Sibanyoni M: Treatment of oral thrush in HIV/AIDS patients with lemon juice and lemon grass (Cymbo-pogon citratus) and gentian violet. Phyto-medicine 2009;16:118-124.
33. Horsfield P, Logan FA, Newey JA: Letter: Oral irritation with gentian violet. Br Med J 1976;ii:529.